Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 13/20 | 0.64 |
| ▸ | CDK2 | P24941 | 13/20 | 0.64 |
| ▸ | CCNA1 | P78396 | 13/20 | 0.64 |
| ▸ | IKBKB | O14920 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA4 | P22748 | 4/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6660718 | 0.85 | CA9 (0.55) | CCNA2CDK2CCNA1IKBKBPTGS2 | |
| SCHEMBL13238794 | 0.84 | PTGS2 (0.47) | CCNA2CDK2CCNA1IKBKBPTGS2 | |
| SCHEMBL14747600 | 0.81 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL5334053 | 0.78 | CCNA2 (0.62) | CCNA2CDK2CCNA1IKBKBPTGS2 | |
| SCHEMBL6794909 | 0.78 | CCNA2 (0.62) | CCNA2CDK2CCNA1IKBKBPTGS2 | |
| SCHEMBL5227494 | 0.78 | CCNA2 (1.00) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL6791456 | 0.78 | CCNA2 (0.62) | CCNA2CDK2CCNA1IKBKBPTGS2 | |
| SCHEMBL6663541 | 0.78 | CCNA2 (0.65) | CCNA2CDK2CCNA1IKBKBPTGS2 | |
| SCHEMBL8937493 | 0.76 | PTGS2 (0.69) | CCNA2CDK2CCNA1IKBKBPTGS2 | |
| SCHEMBL5335359 | 0.75 | CCNA2 (0.58) | CCNA2CDK2CCNA1IKBKBPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| EP-1476431-A1 | TRICYCLIC PYRAZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003070706-A1 | TRICYCLIC PYRAZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | CCNA2 645/4885CDK2 294/4885CCNA1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.